RedHill Biopharma

RedHill BioPharma lead drug making its way towards FDA approval

RedHill Biopharma (NASDAQ:RDHL) CEO Dror Ben-Asher sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Quick facts: RedHill Biopharma

Price: $6.86

Market: NASDAQ
Market Cap: $194.61 m


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 2 hours ago

2 min read